LUKAS SCHEIBLER - 21 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: CHIEF INNOVATION OFFICER
Signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler
Issuer symbol: APLS
Transactions as of: 21 Jan 2022
Net transactions value: +$80,751
Form type: 4
Filing time: 24 Jan 2022, 16:26:55 UTC
Previous filing: 11 Jun 2021
Next filing: 01 Feb 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$80,751	+3,021	+11%	$26.73	29,681	21 Jan 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-3,021	-2.2%	$0.000000	134,497	21 Jan 2022	Common Stock	3,021	$26.73	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was granted on April 13, 2018 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.